Main Conference – Day 1Wednesday, 18 March 2026 - CET (Central European Time, GMT+01:00)

• Developing self-assembling siRNA therapeutics designed for effective and targeted delivery via inhalation to treat respiratory diseases.
• Optimizing siRNA formulations to ensure stability, efficient pulmonary uptake, and minimal off-target effects.
• Demonstrating safety and therapeutic efficacy through advanced preclinical models of respiratory disease

Emerging extra‑hepatic delivery platforms are extending the therapeutic reach of oligonucleotides by enabling selective tissue and cell targeting. Novel chemistries are enhancing molecular stability, cellular uptake and potency, while minimising off‑target effects. Bioconjugation strategies, including transferrin receptor–mediated targeting and antibody–oligonucleotide conjugates, are promising new approaches. Together, these innovations are accelerating the development of safer, more effective oligonucleotide therapeutics